Showing results (171-180 of 218) with videos related to
Sort By:
Pageof 22
Oncology Research and Treatment|October 22, 2019
Influence of Taxanes on Treatment Sequence in Gastric CancerSylvie Lorenzen, Michael Stahl, Ralf-Dieter Hofheinz, et al.BMC Cancer|October 23, 2016
Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)Arndt Vogel, Josefine Römmler-Zehrer, Jack Shiansong Li, et al.EMBO Reports|August 22, 2009
Hsp90 is regulated by a switch point in the C-terminal domainMarco Retzlaff, Michael Stahl, H Christian Eberl, et al.Radiation Oncology (London, England)|May 28, 2011
Curative treatment of oesophageal carcinoma: current options and future developmentsMaria C Wolf, Michael Stahl, Bernd J Krause, et al.Journal of Molecular Biology|November 28, 2009
Structural basis of the action of glucosyltransferase Lgt1 from Legionella pneumophilaWei Lü, Juan Du, Michael Stahl, et al.Genes & Development|August 18, 2009
Characterization of the rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesisAlexandre Huber, Bernd Bodenmiller, Aino Uotila, et al.Anticancer Research|June 25, 2003
C-myc gene amplification in different stages of oesophageal squamous cell carcinoma: prognostic value in relation to treatment modalityMonika Bitzer, Michael Stahl, Jawed Arjumand, et al.Onkologie|April 18, 2009
Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primaryKatharina Schuette, Gunnar Folprecht, Albrecht Kretzschmar, et al.Journal of Cancer Research and Clinical Oncology|October 1, 2008
Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO groupKarin Oechsle, Carsten Bokemeyer, Jörg T Hartmann, et al.Pharmacology Research & Perspectives|April 26, 2020
Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double-blind trialChris Wynne, Christian Schwabe, Emmanuelle Vincent, et al.Pageof 22